Jean-Jacques Kiladjian/LinkedIn
Dec 8, 2025, 14:46
Jean Jacques Kiladjian Presents 1st Results of the ROP-ET Study at ASH25
Jean Jacques Kiladjian, Head of Clinical Research Department of Inserm, shared on LinkedIn:
”Proud to have presented at American Society of Hematology ASH25 , on behalf of my co-investigators from 10 European countries, the first results of the ROP-ET study showing that ropeginterferon-alpha 2b is also an effective and safe treatment for patients with essential thrombocythemia ET who have no other therapeutic option.
At 12 months: 65% of durable (>3 months) complete hematologic response, no disease progression, only 1.5% of major thrombotic events, symptoms improvement in 62% of patients.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria